Department of Pharmacology and INSERM U970, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, 56 rue Leblanc, Paris 75015, France Research & Development Department, Pennine Acute Hospitals NHS Trust, Crumpsall, Manchester, UK.
Diabetes, Cardiovascular Medicine & Nutrition, King's College University of London & King's Health Partners, London, UK
Eur Heart J. 2014 Nov 21;35(44):3122-33. doi: 10.1093/eurheartj/ehu293. Epub 2014 Aug 11.
Estimated central systolic blood pressure (cSBP) and amplification (Brachial SBP-cSBP) are non-invasive measures potentially prognostic of cardiovascular (CV) disease. No worldwide, multiple-device reference values are available. We aimed to establish reference values for a worldwide general population standardizing between the different available methods of measurement. How these values were significantly altered by cardiovascular risk factors (CVRFs) was then investigated.
Existing data from population surveys and clinical trials were combined, whether published or not. Reference values of cSBP and amplification were calculated as percentiles for 'Normal' (no CVRFs) and 'Reference' (any CVRFs) populations. We included 45,436 subjects out of 82,930 that were gathered from 77 studies of 53 centres. Included subjects were apparently healthy, not treated for hypertension or dyslipidaemia, and free from overt CV disease and diabetes. Values of cSBP and amplification were stratified by brachial blood pressure categories and age decade in turn, both being stratified by sex. Amplification decreased with age and more so in males than in females. Sex was the most powerful factor associated with amplification with 6.6 mmHg (5.8-7.4) higher amplification in males than in females. Amplification was marginally but significantly influenced by CVRFs, with smoking and dyslipidaemia decreasing amplification, but increased with increasing levels of blood glucose.
Typical values of cSBP and amplification in a healthy population and a population free of traditional CVRFs are now available according to age, sex, and brachial BP, providing values included from different devices with a wide geographical representation. Amplification is significantly influenced by CVRFs, but differently in men and women.
估算中心收缩压(cSBP)和放大率(肱动脉收缩压-cSBP)是潜在预测心血管疾病的非侵入性指标。目前尚无全球性的多设备参考值。我们旨在建立一种适用于全球一般人群的参考值,以标准化不同测量方法之间的差异。然后,我们研究了这些值如何因心血管危险因素(CVRFs)而显著改变。
合并了来自人群调查和临床试验的现有数据,无论是否已发表。将 cSBP 和放大率的参考值计算为“正常”(无 CVRFs)和“参考”(任何 CVRFs)人群的百分位数。我们从 53 个中心的 77 项研究中纳入了 82930 名受试者中的 45436 名。纳入的受试者显然是健康的,没有接受高血压或血脂异常治疗,并且没有明显的心血管疾病和糖尿病。根据臂部血压类别和年龄十年依次对 cSBP 和放大率进行分层,两者均按性别分层。放大率随年龄而降低,男性比女性降低更明显。性别是与放大率最相关的因素,男性比女性高 6.6mmHg(5.8-7.4)。放大率受到 CVRFs 的轻微但显著影响,吸烟和血脂异常降低了放大率,但随着血糖水平的升高而增加。
根据年龄、性别和臂部血压,现在可提供健康人群和无传统 CVRFs 人群的典型 cSBP 和放大率值,这些值包括来自不同设备的具有广泛地理代表性的值。放大率受 CVRFs 的影响显著,但男性和女性的影响不同。